Abstract

The specific aims of the Heartland Cancer Research NCORP are to: To be the primary vector for delivering, implementing, and executing NCI approved cancer treatment clinical trials; cancer prevention, screening and control clinical trials; and Cancer Care Delivery Research clinical trials to a large Midwestern rural and urban population; Enhance Midwestern cancer care by providing convenient access for patients to a region-wide high standard of multidisciplinary integrated cancer care delivery; Participate in pilot studies for NCORP research bases and provide feedback on proposed trials. Participate in NCI-sponsored tissue acquisition and biobanking studies, including those related to the Cancer Moonshot initiative. Reach out to underserved and vulnerable populations across Illinois and Missouri to improve access to cancer clinical trials, state of the art care, and cancer prevention and early detection strategies; Coordinate with local and state agencies to leverage resources to improve state wide cancer education regarding cancer prevention, early detection, treatment and clinical trials; Improve cancer prevention, treatment, screening, and survivorship education for healthcare professionals throughout Illinois and Missouri. Educate healthcare providers across rural and urban Illinois and Missouri regarding cancer clinical trials and incorporation of new findings into daily patient care. Continue to recruit, train, and support new investigators and clinical research staff who share the vision and embrace the objectives of the Heartland NCORP. Explore and share best practices for improving the productivity of Heartland NCORP within an environment of limited resources.

Public Health Relevance

The Heartland Cancer Research NCORP (Heartland NCORP) will be the premier community cancer research organization of the states of Illinois and Missouri by providing state of the art cancer clinical trials, cancer care delivery research, interdisciplinary cancer treatment planning, and coordinated biomarker driven research throughout our service region. Cancer patients, in specific, will benefit as a direct result of these clinical trials, and the consequential knowledge on preventing and treating malignancy in community settings will improve patient care.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Clinical Research Cooperative Agreements - Single Project (UG1)
Project #
2UG1CA189830-06
Application #
9767945
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Parker, Bernard W
Project Start
2014-08-01
Project End
2025-07-31
Budget Start
2019-08-09
Budget End
2020-07-31
Support Year
6
Fiscal Year
2019
Total Cost
Indirect Cost

  Institution

Name
Decatur Memorial Hospital
Department
Type
DUNS #
046584991
City
Decatur
State
IL
Country
United States
Zip Code
62526

  Publications

McCleary, Nadine J; Hubbard, Joleen; Mahoney, Michelle R et al. (2018) Challenges of conducting a prospective clinical trial for older patients: Lessons learned from NCCTG N0949 (alliance). J Geriatr Oncol 9:24-31
West, Howard L; Moon, James; Wozniak, Antoinette J et al. (2018) Paired Phase II Studies of Erlotinib/Bevacizumab for Advanced Bronchioloalveolar Carcinoma or Never Smokers With Advanced Non-Small-cell Lung Cancer: SWOG S0635 and S0636 Trials. Clin Lung Cancer 19:84-92
Miller, Kathy D; O'Neill, Anne; Gradishar, William et al. (2018) Double-Blind Phase III Trial of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node-Positive and High-Risk Lymph Node-Negative Breast Cancer (E5103). J Clin Oncol 36:2621-2629
Henry, N Lynn; Unger, Joseph M; Schott, Anne F et al. (2018) Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor-Associated Arthralgias in Early-Stage Breast Cancer: SWOG S1202. J Clin Oncol 36:326-332
Sekeres, Mikkael A; Othus, Megan; List, Alan F et al. (2017) Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117. J Clin Oncol 35:2745-2753
Basch, Ethan; Dueck, Amylou C; Rogak, Lauren J et al. (2017) Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials. JAMA Oncol 3:1043-1050
Danilov, Alexey V; Li, Hongli; Press, Oliver W et al. (2017) Feasibility of interim positron emission tomography (PET)-adapted therapy in HIV-positive patients with advanced Hodgkin lymphoma (HL): a sub-analysis of SWOG S0816 Phase 2 trial. Leuk Lymphoma 58:461-465
Martin, P; Jung, S-H; Pitcher, B et al. (2017) A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin's lymphoma (NHL): CALGB 50803 (Alliance). Ann Oncol 28:2806-2812
Moinpour, Carol M; Unger, Joseph M; Ganz, Patricia A et al. (2017) Seven-year follow-up for energy/vitality outcomes in early stage Hodgkin's disease patients treated with subtotal lymphoid irradiation versus chemotherapy plus radiation: SWOG S9133 and its QOL companion study, S9208. J Cancer Surviv 11:32-40
Wakelee, Heather A; Dahlberg, Suzanne E; Keller, Steven M et al. (2017) Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol 18:1610-1623

Showing the most recent 10 out of 30 publications